Abstract:Background: Diabetes correlates with poor prognosis in patients with COVID-19, but very few studies have evaluated whether impaired fasting glucose (IFG) is also a risk factor for the poor outcomes of patients with COVID-19. Here we aimed to examine the associations between IFG and diabetes at admission with risks of complications and mortality among patients with COVID-19.Methods: In this multicenter retrospective cohort study, we enrolled 312 hospitalized patients with COVID-19 from 5 hospitals in Wuhan from Jan 1 to Mar 17, 2020. Clinical information, laboratory findings, complications, treatment regimens, and mortality status were collected. The associations between hyperglycemia and diabetes status at admission with primary composite end-point events (including mechanical ventilation, admission to intensive care unit, or death) were analyzed by Cox proportional hazards regression models.Results: The median age of the patients was 57 years (interquartile range 38–66), and 172 (55%) were women. At the time of hospital admission, 84 (27%) had diabetes (and 36 were new-diagnosed), 62 (20%) had IFG, and 166 (53%) had normal fasting glucose (NFG) levels. Compared to patients with NFG, patients with IFG and diabetes developed more primary composite end-point events (9 [5%], 11 [18%], 26 [31%]), including receiving mechanical ventilation (5 [3%], 6 [10%], 21 [25%]), and death (4 [2%], 9 [15%], 20 [24%]). Multivariable Cox regression analyses showed diabetes was associated increased risks of primary composite end-point events (hazard ratio 3.53; 95% confidence interval 1.48–8.40) and mortality (6.25; 1.91–20.45), and IFG was associated with an increased risk of mortality (4.11; 1.15–14.74), after adjusting for age, sex, hospitals and comorbidities.Conclusion: IFG and diabetes at admission were associated with higher risks of adverse outcomes among patients with COVID-19.

A glucose-like metabolite deficient in diabetes inhibits cellular entry of SARS-CoV-2

Imatinib and methazolamide ameliorate COVID-19-induced metabolic complications via elevating ACE2 enzymatic activity and inhibiting viral entry

The potential effects of clinical antidiabetic agents on SARS-CoV-2

COVID-19 induces new-onset insulin resistance and lipid metabolic dysregulation via regulation of secreted metabolic factors

SARS-CoV-2 exploits host DGAT and ADRP for efficient replication

COVID-19 Metabolism: Mechanisms and Therapeutic Targets.

The Serum Metabolome of COVID-19 Patients is Distinctive and Predictive

Diabetes and susceptibility to COVID-19: Risk factors and preventive and therapeutic strategies

Potential Effects of Hyperglycemia on SARS-CoV-2 Entry Mechanisms in Pancreatic Beta Cells

Diabetes and coronavirus (SARS-CoV-2): Molecular mechanism of Metformin intervention and the scientific basis of drug repurposing

Glycolytic inhibitor 2-deoxy-d-glucose attenuates SARS-CoV-2 multiplication in host cells and weakens the infective potential of progeny virions

Impaired glucose metabolism in patients with diabetes, prediabetes, and obesity is associated with severe COVID‐19

Targeting glucose metabolism for treatment of COVID-19

Acute and long-term disruption of glycometabolic control after SARS-CoV-2 infection

SARS-CoV-2 in the pancreas and the impaired islet function in COVID-19 patients

Hyperglycemia-induced cathepsin L maturation: Linking to diabetic comorbidities and COVID-19 mortality

Type 2 Diabetes Contributes to Altered Adaptive Immune Responses and Vascular Inflammation in Patients With SARS-CoV-2 Infection

Interaction of Severe Acute Respiratory Syndrome Coronavirus 2 and Diabetes

GP73 is a glucogenic hormone contributing to SARS-CoV-2-induced hyperglycemia

Hyperglycemia induced cathepsin L maturation linked to diabetic comorbidities and COVID-19 mortality

Impaired Fasting Glucose and Diabetes Are Related to Higher Risks of Complications and Mortality Among Patients With Coronavirus Disease 2019